FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application to update the labeling for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

SUPPL AP for ICLUSIG (PONATINIB HYDROCHLORIDE)